Susanna Naggie, MD

Professor of Medicine
Vice Dean for Clinical Research
Member in the Duke Clinical Research Institute
Campus mail 300 West Morgan St, Suite 800, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Younossi, Zobair, Maria Stepanova, Mark S. Sulkowski, Susanna Naggie, and Sharon L. Hunt. “Patient-Reported Outcomes (PROs) in HIV-HCV Co-infected Patients Treated with Sofosbuvir (SOF)-containing Regimens.” In Hepatology, 60:891A-891A. WILEY-BLACKWELL, 2014.

Scholars@Duke

Sulkowski, Mark S., Maribel Rodriguez-Torres, Jacob P. Lalezari, W Jeffrey Fessel, Karam Mounzer, Margaret C. Shuhart, Anne Luetkemeyer, et al. “All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1).” In Hepatology, 58:313A-314A. WILEY-BLACKWELL, 2013.

Scholars@Duke

Osinusi, Anuoluwapo, and Susanna Naggie. “Boceprevir for HCV in patients with HIV: where next?” Lancet Infect Dis 13, no. 7 (July 2013): 563–64. https://doi.org/10.1016/S1473-3099(13)70162-2.

PMID
23768748
Full Text

Naggie, Susanna. “Management of hepatitis C virus infection: the basics.” Top Antivir Med 20, no. 5 (December 2012): 154–61.

PMID
23363693
Scholars@Duke

Naggie, Susanna, Anu Osinusi, Tiffany Himmel, Joseph Lucas, J. W. Thompson, Laura G. Dubois, Martin A. Moseley, Paul J. Clark, Shyam Kottilil, and Keyur Patel. “Targeted proteomics signature identifies corticosteroid binding globulin peptides as highly predictive of treatment response in IL28B unfavorable genotype patients.” In Hepatology, 56:999A-1000A. WILEY-BLACKWELL, 2012.

Scholars@Duke

Clark, Paul J., Rosanna Santoro, Valeria Piazzolla, Leonardo Mottola, D. Bacca, N. Dello Iacono, Salvatore Grimaldi, et al. “Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C.” In Hepatology, 56:1028A-1029A. WILEY-BLACKWELL, 2012.

Scholars@Duke

Jones, Lisa, Dawn Piercy, Susanna Naggie, and Manal Abdelmalek. “Drug-Induced Idiopathic Portal Hypertension Mimicking “Cryptogenic” Cirrhosis in a HIV Patient.” In American Journal of Gastroenterology, 107:S426–S426. Ovid Technologies (Wolters Kluwer Health), 2012. https://doi.org/10.14309/00000434-201210001-01053.

Full Text

Osinusi, Anu, Aarthi Chary, Mark A. Winters, Susanna Naggie, Henry Masur, Michael A. Polis, Shyam Kottilil, and Mark Holodniy. “IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.” J Med Virol 84, no. 10 (October 2012): 1522–27. https://doi.org/10.1002/jmv.23376.

PMID
22930497
Full Text

Clark, P. J., A. J. Thompson, Q. Zhu, D. M. Vock, M. Zhu, K. Patel, S. A. Harrison, et al. “Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479)).” Digestive Diseases and Sciences 57, no. 9 (September 1, 2012): 2479. https://doi.org/10.1007/s10620-012-2309-y.

Full Text

Pages